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The National Committee on Confidential Enquiries into Maternal 
Deaths recently received notification of a death in South Africa (SA) 
caused by inadvertent intrathecal administration of tranexamic acid 
(TXA). This case highlights a growing clinical risk, of which all 
operating theatre staff should be aware. Review of existing operating 
theatre drug handling practices is required in order to minimise this 
risk.
TXA is included in the World Health Organization (WHO) 
essential medicines list (EML)[1] as well as the SA National 
Department of Health EML.[2] It is a synthetic lysine analogue 
that acts to reduce fibrinolysis through competitive inhibition 
of plasminogen binding sites. TXA is increasingly being used in 
the perioperative setting as a result of recently updated WHO 
guidelines recommending early use of intravenous TXA during 
caesarean delivery (CD) when excessive bleeding occurs.[3] The 
key messages from this guideline are summarised in Table 1. This 
change in practice is largely due to the results of the WOMAN 
trial, a landmark multicentre study including 20 000 patients 
that showed reduced maternal mortality due to bleeding with 
the early administration of TXA in the setting of postpartum 
haemorrhage. [4] The WOMAN trial showed that if TXA was given 
intravenously within 3 hours of bleeding following normal vaginal 
delivery or CD, maternal mortality was reduced by 31%, although 
the absolute reduction was small (1.7 - 1.2%, risk ratio 0.69, 95% 
confidence interval 0.52 - 0.91; p=0.008). These benefits were most 
pronounced in low- and middle-income settings such as SA.[4] The 
WHO states that ‘regardless of the level of health system resources, 
TXA should be recognized as a lifesaving intervention and be made 
readily available for the management of postpartum haemorrhage 
in settings where emergency obstetric care is provided’.[3]
SA TXA recommendations
It has been suggested that the high number of deaths due to obstetric 
haemorrhage (OH) at or after CD in SA is a national emergency,[5] 
and despite a recent downward trend, OH remains the third most 
common cause of maternal mortality at ~17%.[6] Accordingly, the 
nationally endorsed training programme for obstetric emergencies 
(Essential Steps in the Management of Obstetric Emergencies: 
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Table 1. Key messages adapted from the updated World Health Organization recommendations on TXA for the treatment of 
postpartum haemorrhage[3]
• Bleeding during CD is defined as a clinical estimate of blood loss >1 000 mL, or blood loss sufficient to cause haemodynamic instability.
• Early use of TXA (within 3 hours of birth), in addition to standard care, is recommended. The use of TXA >3 hours after birth is not supported.
• Administer TXA 1 g IV over 10 minutes, with a repeat dose if bleeding continues after 30 minutes, or if bleeding restarts within 24 hours of the 
first dose. Only IV use is currently supported.
• TXA should be given in all cases of postpartum haemorrhage, regardless of cause.
• TXA should not be given when a clear contraindication exists, such as thromboembolic disease during pregnancy.
TXA = tranexamic acid; CD = caesarean delivery; IV = intravenous.
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ESMOE)[7] has been revised to recommend early intravenous 
administration of 1 g TXA for bleeding during or after CD. Excessive 
bleeding is now defined as >500 mL in the suction bottle, or a decrease 
in blood pressure accompanied by a rise in heart rate associated with 
bleeding, as detected by the anaesthetist. This is earlier than the 
traditional description of at least 1 000 mL blood loss during CD, and 
TXA is therefore being used with greater frequency. While there may 
be a role for the administration of TXA before CD,[8,9] there is not 
yet enough evidence from high-quality research to recommend such 
prophylaxis at a national level.[10] In particular, there is no evidence 
that prophylactic TXA before CD reduces maternal death.
With increased availability and use of TXA during and immediately 
following CD, the risk of drug error increases. Our case of maternal 
death was assessed by independent experts to be due to intrathecal 
TXA, and occurred in the context of a disturbing international trend. 
A recent review in Anaesthesia[11] highlighted 21 such cases between 
1988 and 2018, 10 of which were fatal. Twenty were due to ‘ampoule 
error’. An accompanying editorial[12] entitled ‘Spinal tranexamic 
acid – a new killer in town’ highlighted the dramatic increase in the 
number of cases since 2009. Seven cases involved CD, 6 of which 
resulted in death: it appears that mortality is higher following CD 
than following other surgery. The authors mention anecdotal reports 
of further cases that have not been formally reported, making the true 
incidence hard to estimate. Clinicians are understandably reluctant 
to submit case reports relating to serious medical error. Additionally, 
cases such as ours that come to light through a confidential enquiry 
process cannot be published in detail owing to requirements to 
maintain anonymity. The incidence is therefore probably far higher 
than currently reported.
Consequences of intrathecal TXA 
administration
Intrathecal TXA is a potent neurotoxin and neurological sequelae 
dominate the clinical presentation, usually with refractory seizures. 
Massive sympathetic stimulation frequently occurs, often leading 
to lethal cardiac arrhythmias such as ventricular fibrillation. 
Treatment is mainly supportive and should occur in an intensive care 
setting, including antiepileptics such as diazepam, thiopentone and 
magnesium sulphate[13] and appropriate antiarrhythmic medication. 
Early cerebrospinal fluid (CSF) lavage is also recommended, 
following success in the management of similar cases.[11,14,15] CSF 
lavage consists of removing 10 mL of CSF and replacing this with 10 
mL of saline, repeated up to four times.[14,15] The increased mortality 
rate in the obstetric population following intrathecal TXA is possibly 
due to decreased CSF volume in pregnancy, leading to increased drug 
concentrations.[11]
Given the consequences of inadvertent intrathecal TXA 
administration, is the increased risk justifiable? TXA has become 
an integral part of the management of OH: the WOMAN trial[4] 
suggested that a maternal life could be saved with every 267 usages 
following OH. The potential ‘number needed to harm’ is difficult 
to estimate: Palanisamy and Kinsella[12] estimate the risk due to 
drug error to be <1 in 10  000 spinal anaesthetics, although this is 
necessarily based on a large degree of conjecture. In Africa, the 
incidence of severe bleeding during or after CD is almost 6%, while 
70% of all complications and 25% of all deaths are secondary to 
bleeding complications.[16] With a lower recommended threshold for 
the use of TXA, it is likely that the drug will be given in >6% of cases. 
The benefits clearly outweigh the risks: the focus therefore needs to 
be on minimising or eliminating drug error.
Minimising the risk of intrathecal 
drug error
The incidence of perioperative drug errors ranges from one in 133 
anaesthetics in retrospective studies[17] to one in two operations in 
prospective studies (one in 20 drug administrations).[18] Obstetric 
neuraxial drug administration errors in particular may result in 
devastating consequences.[19] There is a lack of randomised controlled 
trials that examine specific techniques and their ability to reduce drug 
error; recommendations are therefore based on expert opinion and 
best available evidence.[20,21]
All health facilities should ensure that they have clearly written 
policies that minimise medication errors, and then audit and appraise 
errors that do occur.[22] This approach should nurture a culture 
of drug safety, including multidisciplinary involvement, ongoing 
education and specific evidence-based interventions.[22] However, 
despite vociferous calls for changes in practice, merely exhorting 
doctors to be more careful is often inadequate.[23] Ideally, system 
changes should make it impossible for error to occur. A similar 
problem has been encountered with epidural anaesthesia, where the 
use of Luer universal connectors has allowed for cross-connectivity, 
resulting in drug errors. This problem is easily preventable with the 
use of non-Luer connectors, although uptake has been slow.[23] Non-
Luer connectors will not prevent a single-shot spinal anaesthesia drug 
error, however, as occurs with TXA.
The risk of accidental use of the wrong drug increases when 
ampoules look similar, or are physically available in close proximity. [24] 
There are now a large number of generic versions of TXA, and 
changes in supplier and the appearance of ampoules are increasingly 
common. Human error is to some degree unavoidable, and rather 
than attempting to eliminate all mistakes, strategies should aim to 
reduce predictable errors. Solutions that minimise the possibility of 
human error should be given highest priority.[24] Technology-assisted 
drug identification, using barcode readers, is one such intervention, 
although it is unlikely to be immediately available in SA facilities. Pre-
filled syringes may be another, although this may be problematic for 
manufacturers, as each drug must be tested for stability in a pre-filled 
syringe. Other solutions include the careful reading and labelling of 
syringes, and a second person or device checking the drug.[19] More 
costly methods, such as commercially prepared spinal anaesthesia 
trays including bupivacaine, are unlikely to represent solutions for 
low- and middle-income countries such as SA. Most importantly, the 
physical location of TXA must minimise the potential for drug error. 
There are numerous drugs in theatre that should never be injected 
intrathecally; we need to ensure that TXA is one of these. Avoiding 
a drug substitution error mandates meticulous attention to drug 
checking systems, and above all ensuring that TXA is not kept on or 
near the spinal anaesthesia trolley. Consideration should be given to 
storing TXA out of theatre, provided that the drug will be available 
immediately when requested.
We have made recommendations in Table 2 summarising key 
interventions aimed at reducing drug error from the relevant 
literature.[12,19-22,25]
Importantly, this clinical alert applies equally to both the private 
and public sectors in SA, where different versions and appearances 
of the drug ampoules are available. Fig. 1 illustrates the current 
appearances of TXA and bupivacaine in the state sector in KwaZulu-
Natal Province. Fig. 2 illustrates the TXA used by one of the private 
hospitals in KwaZulu-Natal. This image was taken after discovering 
these ampoules in the same container, illustrating the potential for 
drug error.
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Conclusions
The indications for TXA during and after CD continue to expand. 
The increased use and availability of the drug have led to a concerning 
increase in inadvertent intrathecal administration worldwide – an 
error that always results in harm. We need to urgently raise awareness 
of this potentially lethal mistake and take steps to ensure that we 
have no further such cases in SA. The first step is to store TXA in a 
separate location from spinal bupivacaine, and ensure that the drug 
is never present on the spinal anaesthesia trolley.
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Table 2. Recommendations for preventing TXA drug errors during and immediately after caesarean delivery
• Raise awareness in health facilities (private and public), both written and verbal. Display a clinical alert warning in operating theatres.
• Ensure that warnings reach all cadres of staff involved in CDs, whether in an anaesthetic, surgical, nursing or pharmaceutical role.
• Conduct regular in-service training of all health professionals on how to avoid drug errors. In the SA context, this should be included in the 
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• Use bar coding and scanner identification or pre-filled syringes if capacity exists.
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medication preparation.
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• Minimise staff fatigue.
TXA = tranexamic acid; CDs = caesarean deliveries; SA = South African; ESMOE = Essential Steps in the Management of Obstetric Emergencies; EOST = Emergency Obstetric Simulation Training.
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